

UC Berkeley

UC Berkeley Previously Published Works

Title

Acceptability and feasibility of leveraging community-based HIV counselling and testing platforms for same-day oral PrEP initiation among adolescent girls and young women in Eastern Cape, South Africa

Permalink

<https://escholarship.org/uc/item/6sf0b3ng>

Journal

Journal of the International AIDS Society, 25(7)

ISSN

1758-2652

Authors

Medina-Marino, Andrew

Bezuidenhout, Dana

Ngwepe, Phuti

[et al.](#)

Publication Date

2022-07-01

DOI

10.1002/jia2.25968

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

RESEARCH ARTICLE

Acceptability and feasibility of leveraging community-based HIV counselling and testing platforms for same-day oral PrEP initiation among adolescent girls and young women in Eastern Cape, South Africa

Andrew Medina-Marino^{1,2,3,§,||}, Dana Bezuidenhout^{2,4,||}, Phuti Ngwepe^{2,5}, Charl Bezuidenhout^{2,6}, Shelley N. Facente⁷, Selly Mabandla⁸, Sybil Hosek⁹, Francesca Little⁵, Connie L. Celum¹⁰ and Linda-Gail Bekker¹

§ **Corresponding author:** Andrew Medina-Marino, Desmond Tutu Health Foundation-Eastern Cape Office, 16 Surrey Rd, Vincent, East London 5217, South Africa. (andrewmedinamarino@gmail.com)

|| Denotes equal contribution by authors.

Abstract

Introduction: Community-based delivery of HIV pre-exposure prophylaxis (PrEP) to South African adolescent girls and young women's (AGYW) could increase access but needs evaluation. We integrated PrEP services via home-based services and pop-up tents into existing community-based HIV testing services (CB-HTS) in Eastern Cape Province, South Africa.

Methods: After accessing CB-HTS via a "pop-up" tent or home-based services, HIV-negative AGYW aged 16–25 years were invited to complete a baseline questionnaire and referred for PrEP services at a community-based PrEP site co-located with pop-up HTS tents. A 30-day supply of PrEP was dispensed. PrEP uptake, time-to-initiation, cohort characteristics and first medication refill within 90 days were measured using descriptive statistics.

Results: Of the 1164 AGYW who tested for HIV, 825 (74.3%) completed a questionnaire and 806 (97.7%) were referred for community-based PrEP. Of those, 624 (77.4%) presented for PrEP (482/483 [99.8%] from pop-up HTS and 142/323 [44.0%] from home-based HTS), of which 603 (96.6%) initiated PrEP. Of those initiating PrEP following home-based HTS, 59.1% initiated within 0–3 days, 25.6% within 4–14 days and 15.3% took ≥ 15 days to initiate; 100% of AGYW who used pop-up HTS initiated PrEP the same day. Among AGYW initiating PrEP, 37.5% had a detectable sexually transmitted infection (STI). Although AGYW reported a low self-perception of HIV risk, post-hoc application of HIV risk assessment measures to available data classified most study participants as high risk for HIV acquisition. Cumulatively, 329 (54.6%) AGYW presented for a first medication refill within 90 days of accepting their first bottle of PrEP.

Conclusions: Leveraging CB-HTS platforms to provide same-day PrEP initiation and refill services was acceptable to AGYW. A higher proportion of AGYW initiated PrEP when co-located with CB-HTS sites compared to those referred following home-based HTS, suggesting that proximity of CB-HTS and PrEP services facilitates PrEP uptake among AGYW. The high prevalence of STIs among those initiating PrEP necessitates the integration of STI and HIV prevention programs for AGYW. Eligibility for PrEP initiation should not be required among AGYW in high HIV burden communities. Community-based service delivery will be crucial to maintaining access to PrEP services during the COVID-19 pandemic and future health and humanitarian emergencies.

Keywords: South Africa; PrEP; community-based HIV testing; adolescent girls and young women; differentiated care; HIV prevention

Additional information may be found under the Supporting Information tab of this article.

Received 7 January 2022; Accepted 6 July 2022

Copyright © 2022 The Authors. *Journal of the International AIDS Society* published by John Wiley & Sons Ltd on behalf of the International AIDS Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

1 | INTRODUCTION

Adolescent girls and young women (AGYW) make up 10% of the population in sub-Saharan Africa (SSA), but represent 25%

of new HIV infections in the region [1]. In South Africa, the HIV incidence rate among AGYW is four times higher than adolescent boys and young men (ABYM; 2.54% per year vs. 0.55% per year), and AGYW are twice as likely to be living

with HIV than ABYM [2, 3]. Unfortunately, despite reductions in global HIV incidence, AGYW in SSA continue to bear a disproportionate burden of HIV infections [4].

HIV oral pre-exposure prophylaxis (PrEP) had significant efficacy in clinical trials conducted among different population groups [5–9]. However, young women <25 years had poor efficacy due to poor adherence [10, 11]. Improved PrEP implementation for AGYW will require greater understanding of methods to increase PrEP adherence and persistence among AGYW. The PrEP care cascade provides a framework for understanding PrEP use from a user's perspective, and includes nine steps categorized into three main themes: (1) awareness of PrEP, (2) engaging in PrEP uptake and (3) sustaining adherence and retention in comprehensive PrEP care [12, 13].

Gaps along the PrEP cascade, driven by a variety of behavioural, service delivery, socio-cultural and other structural challenges, continue to limit the number of people who can benefit from PrEP [14]. The cascade drop-off that occurs between awareness and uptake has been associated with distance to PrEP services, HIV and antiretroviral stigma, and lack of PrEP sensitization among key supporters [15–17]. In South Africa, access to PrEP has been predominantly limited to clinic-based settings [17, 19]. Clinic-based PrEP services may provide opportunities for service integration; however, these services are fraught with perceived and real barriers for AGYW, including lack of confidentiality, unfriendly clinic staff, long queues, inconvenient operating hours, lack of privacy, a perceived predominant focus on maternal–child health, insufficient AGYW-friendly services and socio-cultural biases against AGYW sexual behaviours [18–24].

Given that HIV testing is the entry point for PrEP service-delivery, leveraging community-based HIV testing service (CB-HTS) platforms to effectively identify and link AGYW to PrEP services should be considered as an intervention for scaling up PrEP. While previous studies have shown effective linkage from CB-HTS to other HIV prevention services (i.e. voluntary medical male circumcision and family planning) [25–28], none have integrated nor co-located same-day PrEP services into CB-HTS platforms. Given the needs and barriers to sexual and reproductive health services for AGYW, we investigated the acceptability, feasibility and uptake of same-day PrEP services by AGYW when integrated into CB-HTS platforms.

2 | METHODS

This analysis used baseline cohort and implementation data from the Community PrEP Study (CPS), a randomized controlled trial of a behavioural intervention to improve the effective use of PrEP among AGYW [29]. CPS was conducted in two communities, one urban and one rural, in Buffalo City Metro (BCM) Health District, Eastern Cape Province, South Africa. In 2016, BCM had an estimated population HIV prevalence of 12.4% and incidence of 0.54%; an adult (15+ years) HIV prevalence of 17.1% and incidence of 0.74%; and an AGYW (age 15–24 years) HIV prevalence of 12.8% and incidence of 2.40% [30]. A detailed study protocol and methods has been previously published [29]. Note: exposure to a behavioural intervention only occurred at follow-up visits and

did not impact on CB-HTS or enrolment activities described below.

2.1 | HIV testing platforms

Two CB-HTS modalities (i.e. pop-up and home-based testing) were implemented by the study team in the two study communities from 22 October 2018 to 15 November 2019. Pop-up testings ($n = 3$ per community; 1x fixed; 1x semi-mobile; 1x portable testing tent) were positioned at key locations in each study community as previously described [29, 31]. Home-based testing teams systematically visited all households in designated community areas. HIV testing was offered to all community members in accordance with South African national HIV testing guidelines [29, 32].

2.2 | CB-HTS, participant recruitment and retention for first medication refill

After completion of post-test counselling, AGYW aged 16–25 years with negative HIV test results were screened using a standardized script read in English or IsiXhosa (Table S1: Script 1). Eligible individuals (e.g., self-identifying as a woman, aged 16–25 years, HIV-negative test) were then read a second standardized script inviting them to complete a baseline questionnaire (Table S1: Script 2).

Consenting participants were then administered a baseline questionnaire, which included a short 5 minute PrEP informational video featuring AGYW from similar communities (<https://www.youtube.com/watch?v=rHkQq-anmo>) [33]. Upon completion, participants interested in learning more about PrEP were referred to fixed service sites in each study community where they learned more about PrEP services.

Interested participants who presented to the PrEP service sites were provided additional information about PrEP. Those interested in initiating PrEP were further assessed for study eligibility. Inclusion criteria for study participation and PrEP initiation were self-reported: (1) age 16–25 years old, (2) self-identified as female, (3) residing in one of the study communities, (4) HIV negative, (5) fluent in English or IsiXhosa, (6) no plan to move outside of the study community for 12 months and (7) willing and able to provide informed consent. Participants were excluded if they self-reported: (1) being pregnant, (2) breastfeeding, (3) participating in another HIV prevention study, (4) using post-exposure prophylaxis or (5) taking tuberculosis treatment. Due to social desirability bias, structural risk factors and the dynamic nature of HIV risk among South African AGYW, prior sexual activity was not used as inclusion/exclusion criterion [3, 34, 35].

Eligible participants were fully briefed on the study, consented and asked to provide urine and blood specimens [29]. Non-pregnant AGYW were then provided a 30-day supply of DIDIVIR (CIPLA generic for Emtricitabine 200 mg/Tenofovir Disoproxil Fumarate 300 mg). All participants were asked to return for monthly PrEP refills.

Given the recommendation that young people on PrEP may benefit from more frequent visits to support adherence [36] and to encourage return for a first medication refill, participants were invited for an orientation visit 2 weeks post-enrolment to meet with their adherence counsellor, review

test results with a study nurse, assess side effects from PrEP and receive the first of three hepatitis B injections if indicated.

2.3 | Data and specimen collection

A baseline audio computer-assisted self-interviewing questionnaire, administered on a table computer following HTS post-test counselling, collected socio-demographics, behavioural and clinical histories; HIV knowledge, attitudes and practice; and a self-reported HIV risk survey. Implementation indicators for study monitoring were collected using REDCap. Upon study consent to initiate PrEP, urine was collected for pregnancy testing, vaginal swabs were collected to test for sexually transmitted infections (STIs) and blood specimens were collected for hepatitis B antigen, syphilis and creatinine clearance [29].

2.4 | Data analysis

The distributions of individual-level characteristics were calculated using frequency and proportions for discrete variables and medians with interquartile range (IQR) for continuous measures. Significance testing was not conducted because the study was not powered to measure differences in testing modalities. Participant retention for the first medication collection was calculated using the number of participants who attended the visit divided by the study sample size.

To assess factors associated with presentation to a PrEP initiation site following home-based testing and referral, we conducted a multivariable logistic regression model. This analysis was restricted to the home-based modality because there was near-universal same-day initiation from the pop-up testing modality (Figure 2). Variable selection for our model was based on a directed acyclic graph, which included factors hypothesized or documented in the literature to be associated with HIV prevention behaviours and PrEP uptake [37]. First, crude logistic regression was used to estimate associations between presentation and each factor individually. Due to the exploratory nature of this analysis, factors whose p -value was ≤ 0.25 or suggestive in the literature to be significant were included together in a multivariable model to adjust for potential confounding.

Using descriptive statistics, we compared the overall HIV risk profile of our study cohort to that of other PrEP demonstration study cohorts by applying previously used HIV risk assessment measures in a post-hoc analysis [10, 38–40]; of note, we had not collected all variables assessed by these measures. The ICAP risk assessment tool was developed to support the implementation of PrEP; training curriculum and tools were designed to enable clinical providers to attain the skills required to provide PrEP to appropriate candidates [41]. For the ICAP tool to screen for substantial risk of HIV [38], we applied the “sexual activity in a high-prevalence HIV population” criteria plus condomless sex with more than one partner or a history of STIs via self-report, lab test or syndromic screening. The Liverpool VCT, Care and Treatment (LVCT) Health risk assessment tool was developed to identify young women at risk for HIV for the Introducing PrEP into HIV Combination Prevention demonstration project [39]. For the LVCT tool [39], we collected and used five of the seven data

points, including current age, age at first sexual interaction, condom use, STI history and number of sexual partners all in the last 3 months; we did not collect HIV status of sexual partners and pregnancy was a study exclusion criterion. For the VOICE risk assessment score [40, 42], we collected and used six of the seven data points, including age, married or living with partner, partner provides financial/material support, primary sex partner has other partners, any curable STI and alcohol use; we did not collect HSV-2 serological data. Of note, the VOICE risk assessment score was derived from women who participated in the MTN 033/VOICE study, and further assessed using data from women enrolled in MTN 020/ASPIRE [10, 43]. It was validated to predict 1-year risk of HIV acquisition among African women in settings with generalized HIV epidemics, including South Africa; a risk score of ≥ 3 correlated with an HIV incidence of $>3\%$ per year. VOICE was developed to inform targeted scale-up of HIV prevention programs, including PrEP, for women in Eastern and Southern Africa.

All analyses were conducted using STATA 13.1 software (StataCorp, College Station, TX, USA).

2.5 | Ethics approval

Ethics approval was obtained from the University of Cape Town Human Research Ethics Committee (Ref: 289/2018) with permission provided by the Eastern Cape Provincial Department of Health research committee and the BCM District Department of Health.

3 | RESULTS

A total of 1164 AGYW were tested for HIV; 746 (64.1%) via pop-up testing and 418 (35.9%) via home-based testing (Figure 1). Of those, 1111 (95.4%) were read Script 1; 53 (4.55%) tested positive for HIV and were not eligible for further consideration. Of those read Script 1, 254 (22.9%) immediately expressed they did not want to participate in any survey, 11 (1%) were not eligible because they lived outside the study communities and 16 (1.4%) reported they planned to relocate in the next 12 months.

Of the 830 (74.7%) AGYW read Script 2, 826/830 (99.5%) consented to take the baseline questionnaire, 825/830 (99.4%) completed the questionnaire and 806/830 (97.1%) were referred for PrEP initiation services. Of those referred, 624/806 (77.4%) presented to a community-based PrEP initiation site; 482/483 (99.8%) presented from pop-up testing sites and 142/323 (44.0%) presented from home-based testing. Of those who presented, 620/624 (99.4%) provided consent and 603/620 (97.3%) initiated PrEP; 466/479 (97.3%) from pop-up testing and 137/141 (97.2%) AGYW home-based testing (Figure 1). Hundred percent of eligible AGYW from the pop-up testing modality initiated PrEP the same day as introduction. In comparison, 59.1% of home-based testers initiated within 0–3 days, 25.6% initiated within 4–14 days and 15.3% initiated within 15+ days from introduction (Figure 2). There were no significant socio-demographic or behavioural factors that influenced the presentation to a PrEP initiation site from home-based referrals; notably, only participants from home-based referrals




Figure 1. Participant enrolment flow diagram.

were analysed, as 97.3% of participants referred from a mobile site presented for PrEP initiation (Table S2).

The median age of study participants was 18 years (IQR: 4), with the majority attending school and reporting their average monthly income to be less than R1000 (~\$57.80) (Table 1).

Previous HIV testing was self-reported by 562 (93.2%) participants, of which 315 (52.2%) had tested more than three times, and 360 (59.7%) reported testing for HIV within the last 6 months. The median age of sexual debut was 16 years (IQR: 2), with 385 (63.8%) participants reported ever




Figure 2. Time-to-initiation proportions.

engaging in sexual intercourse, and 284 (47.1%) reporting sexual intercourse in the past month; only 120 (20.0%) participants reported always using a condom. The majority of participants ($n = 335$; 55.6%) reported having a primary sex partner. Among those who reported having a primary sex partner, 240 (71.6%) stated that they either knew or were unsure whether their primary sex partner had other sex partners. Though 570 (94.5%) participants had discussed HIV prevention strategies, only 250 (41.5%) had heard of PrEP before our study.

Prior to study enrolment, 113 (18.7%) participants reported ever being treated for an STI. At the time of enrolment, 227 (37.6%) participants had a positive STI test result, of which 134 (59.0%) were asymptomatic. *Chlamydia trachomatis* (CT, $n = 182$; 30.6%) accounted for the highest burden STI, followed by *Neisseria gonorrhoeae* (NG, $n = 59$; 10.0%), *Trichomonas vaginalis* (TV, $n = 42$; 7.1%) and syphilis ($n = 2$, 0.3%) (Table 1). Analysis of participant sexual behaviours and STI test results revealed that of the 218 AGYW with positive STI results who responded to the question about sexual activity, 58 (26.6%) reported never having had sex (Table 1). Furthermore, of 120 participants who reported always using a condom, 41 (34.2%) had a positive STI test result (data not shown).

On a scale of 0 to 10 (0 = no risk; 10 = extreme risk) for self-perceived risk of HIV infection, the median score self-reported by participants was 1 (IQR: 4; range 0–10). When

computing our study population's risk profile from more in-depth risk assessments used during previous PrEP studies [10, 39], 64.2–88.5% of our study population would be considered at high risk of contracting HIV (Table S3).

Implementation indicators are shown in Table S4. The number of AGYW needed to test to identify one AGYW interested in PrEP was 1.51 for pop-up testing services and 1.27 for home-based testing services. To refer one AGYW for PrEP services, 1.54 AGYW needed to be tested at a pop-up testing site, while only 1.29 AGYW needed to be tested through home-based testing services. Finally, in order to initiate one AGYW on PrEP, 1.60 AGYW needed to be tested from a pop-up testing site, while 3.05 AGYW needed to be tested via home-based testing services (Table S4).

Cumulative retention for participants' first medication collection is shown in Table 2. Within the first 30 days of study participation, 229 (38.0%) participants presented for their first medication refill (38.2% of pop-up testing participants and 36.5% of home-based testing participants). Within 60 days of study participation, an additional 78 participants presented for their first medication refill, increasing the cumulative presentation to 50.9% (51.5% of pop-up testing participants and 48.9% of home-based testing participants). Within 90 days of study participation, an additional 22 participants presented for their first medication refill, increasing the cumulative presentation to 54.6% (55.2% of pop-up testing participants and 52.6% of home-based testing participants).

Table 1. Characteristics of study participants stratified by testing modality

Characteristics		Total (603; 100.0%)	Pop-up testing (466; 77.3%)	Home-based testing (137; 22.7%)
Socio-demographic characteristics				
Age (median; IQR)		18 (4)	18 (5)	20 (5)
Current school attendance	Yes	407 (67.5)	334 (71.7)	73 (53.3)
	No	196 (32.5)	132 (28.3)	64 (46.7)
Level of education completed	No formal schooling	35 (5.8)	28 (6.0)	7 (5.1)
	High school	458 (76.0)	355 (76.2)	103 (75.2)
	Above high school and other	105 (17.4)	80 (17.2)	25 (18.2)
Monthly income	≤R1000	444 (73.6)	333 (71.5)	111 (81.0)
	R1001–R4999	47 (7.8)	37 (7.9)	10 (7.3)
	≥R5000	24 (4.0)	21 (4.5)	3 (2.2)
Household size (median; IQR)		5 (3.5)	5 [3]	4 [3]
Location	Urban	303 (50.2)	260 (55.8)	43 (31.4)
	Rural	300 (49.8)	206 (44.2)	94 (68.6)
Behavioural characteristics				
HIV test	Yes	562 (93.2)	431 (92.5)	131 (95.6)
	No	32 (5.3)	27 (5.8)	5 (3.7)
	Don't know	4 (0.7)	4 (0.9)	0 (0.0)
Number of HIV tests ^a	0 times	9 (1.5)	8 (1.7)	1 (0.73)
	1–2 times	234 (38.8)	184 (39.5)	50 (36.5)
	3–4 times	169 (28.0)	135 (29.0)	34 (24.8)
	5 or more times	146 (24.2)	101 (21.7)	45 (32.8)
Time since last test ^a	Less than 3 months ago	254 (42.1)	183 (42.5)	71 (54.2)
	3–6 months ago	106 (17.5)	82 (19.0)	24 (18.3)
	7–12 months ago	59 (9.8)	49 (11.4)	10 (7.6)
	More than 12 months ago	37 (6.1)	28 (6.5)	9 (6.9)
	Cannot recall	86 (14.3)	71 (16.5)	15 (11.5)
Alcohol use	Yes	333 (55.2)	261 (56.0)	72 (52.6)
	No	260 (43.1)	195 (41.9)	65 (47.4)
Drug use	Yes	39 (6.5)	35 (7.5)	4 (2.9)
	No	557 (92.4)	425 (91.2)	132 (96.4)
Ever had sexual intercourse	Yes	385 (63.8)	302 (64.8)	83 (60.6)
	No	179 (29.7)	130 (27.9)	49 (35.8)
Age at sexual debut (median; IQR)		16 (2)	16 (2)	17 (2)
Sexuality ^b	Opposite sex	398 (66.0)	316 (67.8)	82 (59.9)
	Bisexual	8 (1.3)	6 (1.3)	2 (1.5)
	Same sex	9 (1.5)	5 (1.1)	4 (2.9)
Time since last sexual intercourse ^b	Within past week	198 (32.8)	158 (33.9)	40 (29.2)
	Within past month	86 (14.3)	69 (14.8)	17 (12.4)
	1–6 months ago	80 (13.3)	61 (13.1)	19 (13.9)
	7–12 months ago	9 (1.5)	8 (1.7)	1 (0.7)
	More than a year ago	32 (5.3)	22 (4.7)	10 (7.3)
Frequency of condom use ^b	All the time	120 (20.0)	92 (19.7)	28 (20.4)
	Some of the time	230 (38.1)	187 (40.1)	43 (21.4)
	Never	66 (10.9)	49 (10.5)	17 (12.4)

(Continued)

Table 1. (Continued)

Characteristics		Total (603; 100.0%)	Pop-up testing (466; 77.3%)	Home-based testing (137; 22.7%)
Ever received incentive for sex ^c	Yes	120 (19.9)	94 (20.2)	26 (19.0)
	No	54 (9.0)	48 (10.3)	6 (4.4)
	Don't know	110 (18.2)	82 (17.6)	28 (20.4)
Ever had sex with a partner living with HIV ^b	Yes	4 (0.7)	4 (0.9)	0 (0.0)
	No	356 (59.0)	281 (60.3)	75 (54.7)
	Don't know	61 (10.1)	48 (10.3)	13 (9.5)
Primary sex partner	Yes	335 (55.6)	260 (55.8)	75 (54.7)
	No	240 (39.8)	187 (40.1)	53 (38.7)
Primary sex partner has other sex partners ^d	Yes, I know	53 (8.8)	41 (8.8)	12 (8.8)
	Yes, I suspect	90 (14.9)	68 (14.6)	22 (16.1)
	Unknown	124 (20.6)	93 (20.0)	31 (22.6)
	No	94 (15.6)	75 (16.1)	19 (13.9)
	Don't know	2 (0.3)	2 (0.4)	0 (0.0)
Clinical characteristics				
Depression (PHQ9)	Normal (0–4)	229 (38.0)	171 (36.7)	58 (42.3)
	Mild (5–9)	226 (37.5)	177 (38.0)	49 (35.8)
	Moderate (10–14)	113 (18.7)	92 (19.7)	21 (15.3)
	Moderately severe (15–19)	27 (4.5)	21 (4.5)	6 (4.4)
	Severe (20–27)	8 (1.3)	5 (1.1)	3 (2.2)
Creatinine clearance	Positive (<60)	11 (1.8)	10 (2.2)	1 (0.7)
	Negative (>60)	582 (96.5)	447 (95.9)	135 (98.6)
	Missing	10 (1.7)	9 (1.9)	1 (0.7)
Hepatitis B antigen (HBsAg)	Positive	2 (0.3)	1 (0.2)	1 (0.7)
	Negative	579 (96.7)	448 (97.6)	131 (93.6)
	Invalid	17 (2.8)	9 (2.0)	8 (5.7)
	Missing	1 (0.2)	1 (0.2)	0 (0.0)
Ever diagnosed with STI	Yes	113 (18.7)	84 (18.0)	29 (21.2)
	No	480 (79.6)	373 (80.0)	107 (78.1)
STI symptoms ^e	Yes	209 (34.7)	170 (36.5)	39 (28.5)
	No	385 (63.8)	288 (61.8)	97 (70.8)
STI—any	Yes	225 (37.5)	181 (39.1)	44 (32.4)
	No	366 (61.1)	277 (59.8)	89 (65.4)
STI ^e —by infection	CT infection	182 (30.8)	141 (30.8)	41 (30.8)
	NG infection	59 (10.0)	48 (10.5)	11 (8.3)
	TV infection	42 (7.1)	35 (7.6)	7 (5.3)
Syphilis test	Positive	2 (0.3)	2 (0.4)	0 (0.0)
	Negative	600 (99.0)	459 (98.9)	141 (100.0)
	Missing	3 (0.7)	3 (0.7)	0 (0.0)
Knowledge, attitudes, practice and self-perceived risk of HIV				
Positive STI by self-report sexual activity ^f	Had sex	160 (73.4)		N/A
	Never had sex	58 (26.6)		N/A
Ever discussed HIV prevention with anyone	Yes	570 (94.5)	437 (93.8)	133 (97.1)
	No	14 (2.3)	13 (2.8)	1 (0.7)

(Continued)

Table 1. (Continued)

Characteristics		Total	Pop-up testing	Home-based testing
		(603; 100.0%)	(466; 77.3%)	(137; 22.7%)
Ever heard of PrEP	Yes	250 (41.5)	188 (40.3)	62 (45.3)
	No	347 (57.5)	273 (58.6)	74 (54.0)
Knowledge of HIV risk (median; IQR)		3 (3)	3 (3)	2 (4)
Range: 0–7				
Self-perceived HIV risk (median; IQR)		1 (4)	1 (4)	1 (3)
Range: 0–10				

^aN/A for 41/57 participants who have not had an HIV test.

^bN/A for 179 participants who reported never having sex.

^cSex incentives included: money, alcohol/drugs, clothes, airtime, accommodation, transport, better academic grades, school fees and food.

^dN/A for 240 participants who do not have primary sex partner.

^eDenominator is those with a valid test result.

^fDenominator is those with a positive STI test result who did not skip the sexual activity question.

^gSymptom screening performed as per South African national guidelines for syndromic management of STIs.

Table 2. Cumulative participant retention for first medication collection at 30, 60 and 90 days

Time point	Retention					
	Pop-up testing		Home-based testing		Total	
	# Attended	%	# Attended	%	# Attended	%
First refill within 30 days	178/466	38.2%	50/137	36.5%	229/603	38.0%
First refill within 60 days	240/466	51.5%	67/137	48.9%	307/603	50.9%
First refill within 90 days	257/466	55.2%	72/137	52.6%	329/603	54.6%

4 | DISCUSSION

Our study sought to reduce barriers to clinic-based PrEP services for South African AGYW. AGYW in South Africa continue to be at high risk for HIV acquisition [3], with a significant proportion of our participants self-reporting infrequent condom use, transactional sex and not knowing their sexual partner's HIV status. While our study purposefully did not apply HIV risk measures to determine eligibility for initiating PrEP, our post-hoc analysis found that a significant proportion of study participants were at high risk of acquiring HIV speaking to the disconnect between AGYW's self-perceived HIV risk and actual HIV risk. Unequal gender dynamics associated with transactional sex and sexual relationships with older men likely contribute to low levels of condom use for many AGYW [44–46]. Furthermore, the large proportion of study participants who reported receiving incentives for sex likely indicates limited access to financial resources. Given these findings, increased access to community-based PrEP services may better support AGYW to mitigate their risk of HIV infection. High interest in and uptake of PrEP among study participants indicate substantial demand for such services.

AGYW face numerous barriers in obtaining clinic-based sexual and reproductive health services, including perceived or real issues pertaining to confidentiality [47–48], unfriendly clinic staff [48–50], physical access to clinics [51, 52] and social acceptability of sexual activities [53]. We found that co-

location of pop-up HTS and community-based PrEP services resulted in a higher rate of presentation for PrEP services compared to referral following home-based HTS, suggesting that co-located CB-HTS and PrEP services may be preferable to AGYW. Interestingly, HTS modality was not associated with different rates of PrEP initiation nor return for their first medication refill within 90 days (Table S4); however, our previous qualitative assessment identified barriers and facilitators to immediate and delayed presentation to our community-based PrEP service sites [54].

Given the cost and logistics associated with establishing non-clinic, community-based PrEP services (e.g. operational and fixed costs akin to a community pharmacy dispensing site), referrals for clinic-based PrEP services are likely to be more feasible and cost-effective for large-scale HIV prevention programs, especially due to the large number of existing non-government organization and community health worker programs already providing community-based health services in South Africa [33–57]. However, leveraging community-based platforms for other HIV prevention services, such as injectable PrEP, will be strongly influenced by the cold-chain requirements of the injectable formulation. This said, it may be highly amenable to home-based delivery.

Although a growing number of studies and programs are offering same-day PrEP initiation, few have provided AGYW access to PrEP via non-clinical settings [58–61]. Previous studies and population-based programs have shown same-day

initiation rates between 77.0% and 90.8% [59, 60, 62]. In contrast, among pop-up testers offered same-day initiation in our study, 100% initiated PrEP that day; 59.1% of those referred from home-based HTS presented for PrEP within 3 days. Of the 603 participants who initiated PrEP, only 11 (1.8%) had abnormal creatinine clearance results at initiation, further supporting the South African HIV Clinicians Society guidelines to assess creatinine during or after PrEP initiation [63]. Together, these findings support the co-location of CB-HTS and PrEP services offering same-day initiation for AGYW.

PrEP scale-up in South Africa provides an additional opportunity to integrate STI services with HIV prevention. Recent studies in SSA have shown extremely high prevalence and incidence of curable STIs (CT, NG and TV) [64–66]. Almost 90% of those young women and 59.0% of participants in this study were asymptomatic and would have been missed by WHO's syndromic management approach. It is essential to identify improved STI control strategies that are effective, affordable and put STI prevention into AGYW's hands [67]. Acceptable and feasible ways to identify and treat sexual partners are also needed to significantly improve reproductive health outcomes and impact of PrEP.

Of note, our implementation of CB-HTS platforms and concomitant recruitment of participants was concluded prior to the global occurrence of COVID-19 [68], with all participants due for a first medication pick-up prior to 16 February 2020. This was before both the first case of COVID-19 was identified in South Africa and the government's implementation of public health measures, including the national lock-down [69, 70]. Consequently, COVID-19 had no effect or impact on the implementation of our CB-HTS services, recruitment activities or the ability of participants to pick up their first medication refill within 90 days of PrEP initiation. However, a number of studies have shown wide-spread disruptions to clinic-based HIV and PrEP services during the COVID-19 pandemic [71–73]. Community-based service delivery has been shown to improve access to HIV services during previous health and conflict emergencies [74], and when compared to accessing clinic-based services even during non-emergency times [75]. Due to historic over-crowding of primary health clinics, we and others continue to suggest that community-based service delivery is crucial both to minimize COVID transmission in primary health clinics, including to healthcare workers, and to maintain access to PrEP and other HIV care and treatment services during and after the COVID-19 pandemic [71–74, 76–78]. However, the effectiveness and sustainability of such community-based service delivery platforms during and after COVID-19 will depend on the mobilization of health resources.

A significant strength of this study was the ability to leverage widely implemented CB-HTS to assess the acceptability and feasibility of PrEP services provision via non-clinic-based platforms. Towards this, the inclusion of two different CB-HTS platforms was also a strength, as they provided comparative implementation data to inform potential future scale-up activities. This study also has some limitations. First, nearly a third of AGYW with a negative HIV test result immediately declined to hear anything about the study. As such, a rather large number of AGYW potentially eligible for PrEP never had the chance to learn more about PrEP as an HIV

prevention method. Notably, refusal occurred after being read Script 1, which did not include any mention of PrEP; thus, we cannot conclude that refusal had anything to do with lack of interest in PrEP or HIV prevention services. Second, our study was not powered to compare PrEP uptake or persistence between the community-based recruitment modalities. Although observational comparisons were noted, a rigorous evaluation should be performed to determine the most cost-effective delivery model. Third, this study did not have a clinic-based referral comparison to determine how uptake rates may differ between referrals for community- versus clinic-based PrEP services. Although we observed high presentation rates for community-based PrEP services, we cannot conclude that this would be significantly different from the presentation rates for clinic-based PrEP services.

5 | CONCLUSIONS

Leveraging CB-HTS platforms to provide same-day PrEP initiation services is an important addition to existing HIV prevention and testing behaviours of AGYW. CB-HTS was shown to be acceptable and available for AGYW [31]. Despite high HIV incidence in this subgroup, PrEP uptake and adherence has remained low [10]. We report that providing community-based PrEP services directly increases supply-side aspects of the PrEP cascade for AGYW, and leveraging community platforms to increase the knowledge of PrEP services may also increase the demand for PrEP services in this group. Integrating community-based PrEP promotion and services with CB-HTS may ultimately lead to substantial improvement in access and impact of PrEP for AGYW in SSA, helping to reduce HIV-related health inequities currently seen in this population.

AUTHORS' AFFILIATIONS

¹Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa; ²Research Unit, Foundation for Professional Development, Buffalo City Metro, Eastern Cape Province, South Africa; ³Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; ⁴Department of Epidemiology, Mailman School of Public Health, Columbia University, New York City, New York, USA; ⁵Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa; ⁶School of Public Health, Boston University, Boston, Massachusetts, USA; ⁷School of Public Health, University of California, Berkeley, California, USA; ⁸HIV/AIDS, STIs and TB Program, Buffalo City Metro Health District, Eastern Cape Province Department of Health, Bhisho, South Africa; ⁹Departments of Psychiatry and Infectious Disease, Stroger Hospital of Cook County, Chicago, Illinois, USA; ¹⁰Department of Global Health, Medicine and Epidemiology, University of Washington, Seattle, Washington, USA

COMPETING INTERESTS

SNF reports receipt of consulting fees from Gilead Sciences, Inc. for studies unrelated to this current work. Gilead had no influence over the data collection, analysis or reporting of this study.

AUTHORS' CONTRIBUTIONS

AMM and LGB developed the original study concept and design. AMM, LGB, SH, CLC and SNF contributed to the development of the funded NIH grant submission. AMM and CB developed the study concept, design and funding proposal to the Bill and Melinda Gates Foundation via the South African National HIV Think Tank. AMM, CB, DB and PN oversaw all aspects of study implementation. AMM, DB, CB and PN developed the detailed protocol implementation plan and oversaw all study activities and staff. DB, PN and FL were responsible for data management

and analysis. AMM and DB led the writing of the manuscript, and SNF supported manuscript revision. All authors approved the final version of this manuscript.

ACKNOWLEDGEMENTS

We thank Ms. Keabetswe Kodi, Ms. Lungelwa Mlanjeni, Ms. Lindsey de Vos and Mr. Ralph Mawarire of the Foundation for Professional Development for project coordination and support. We thank our field teams for their dedication and hard work. We thank the Buffalo City Metro Department of Health for their support and engagement in ensuring successful implementation of this study.

FUNDING

This research is funded by the National Institute of Mental Health (NIMH) of the U.S. National Institutes of Health under award number R01MH114648 to AMM and LGB. Complementary funding was provided by the Bill and Melinda Gates Foundation through the South African National HIV Think Tank to AMM. The funders had no role in the study design, data collection and analysis, nor will they have any role in manuscript preparations or publication decisions.

DISCLAIMER

The authors wrote the manuscript and had final responsibility for the decision to submit for publication. The funder had no role in design, data collection, analysis, interpretation or writing of the report. The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the donor.

DATA AVAILABILITY STATEMENT

Data may be available upon request.

REFERENCES

1. Joint UN Programme on HIV/AIDS. Miles to go: closing gaps, breaking barriers, righting injustices. Geneva; 2018.
2. Birdthistle I, Tanton C, Tomita A, de Graaf K, Schaffnit SB, Tanser F, et al. Recent levels and trends in HIV incidence rates among adolescent girls and young women in ten high-prevalence African countries: a systematic review and meta-analysis. *Lancet Glob Health*. 2019;7(11):e1521–40.
3. Simbayi L, Zuma K, Zungu N, Moyo S, Marinda E, Jooste S, et al. South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2017: towards achieving the UNAIDS 90-90-90 targets. 2019 [cited 2021 Apr 4]. Available from: <http://repository.hsra.ac.za/handle/20.500.11910/15052>
4. UNAIDS. Global epidemic update: communities at the centre. 2019 [cited 2021 Jul 23]. Available from: https://www.unaids.org/sites/default/files/media_asset/2019-global-AIDS-update_en.pdf
5. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. *N Engl J Med*. 2010;363(27):2587–99.
6. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. *N Engl J Med*. 2012;367(5):399–410.
7. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*. 2013;381(9883):2083–90.
8. Amico KR, Mansoor LE, Corneli A, Torjesen K, van der Straten A. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. *AIDS Behav*. 2013;17(6):2143–55.
9. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. *N Engl J Med*. 2012;367(5):423–34.
10. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodini N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. *N Engl J Med*. 2015;372(6):509–18.
11. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. *N Engl J Med*. 2012;367(5):411–22.
12. Nunn AS, Brinkley-Rubinstein L, Oldenburg CE, Mayer KH, Mimiaga M, Patel R, et al. Defining the HIV pre-exposure prophylaxis care continuum. *AIDS*. 2017;31(5):731–4.
13. Hill LM, Maseko B, Chagomerana M, Hosseinipour MC, Bekker LG, Pettifor A, et al. HIV risk, risk perception, and PrEP interest among adolescent girls and young women in Lilongwe, Malawi: operationalizing the PrEP cascade. *J Int AIDS Soc*. 2020;23(Suppl 3):e25502.
14. Hargreaves JR, Delany-Moretlwe S, Hallett TB, Johnson S, Kapiga S, Bhattacharjee P, et al. The HIV prevention cascade: integrating theories of epidemiological, behavioural, and social science into programme design and monitoring. *Lancet HIV*. 2016;3(7):e318–22.
15. Mayer CM, Owaraganise A, Kabami J, Kwarisiima D, Koss CA, Charlebois ED, et al. Distance to clinic is a barrier to PrEP uptake and visit attendance in a community in rural Uganda. *J Int AIDS Soc*. 2019;22(4):e25276.
16. Jackson-Gibson M, Ezema AU, Orero W, Were I, Ohiomoba RO, Mbullo PO, et al. Facilitators and barriers to HIV pre-exposure prophylaxis (PrEP) uptake through a community-based intervention strategy among adolescent girls and young women in Seme Sub-County, Kisumu, Kenya. *BMC Public Health*. 2021;21(1):1284.
17. Celum CL, Delany-Moretlwe S, Baeten JM, van der Straten A, Hosek S, Bukusi EA, et al. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. *J Int AIDS Soc*. 2019;22(Suppl 4):e25298.
18. Hagey JM, Akama E, Ayieko J, Bukusi EA, Cohen CR, Patel RC. Barriers and facilitators adolescent females living with HIV face in accessing contraceptive services: a qualitative assessment of providers' perceptions in western Kenya. *J Int AIDS Soc*. 2015;18:20123.
19. McLaren ZM, Ardington C, Leibbrandt M. Distance decay and persistent health care disparities in South Africa. *BMC Health Serv Res*. 2014;14:541.
20. Angotti N, Bula A, Gaydos L, Kimchi EZ, Thornton RL, Yeatman SE. Increasing the acceptability of HIV counseling and testing with three C's: convenience, confidentiality and credibility. *Soc Sci Med*. 2009;68(12):2263–70.
21. Mathews C, Gutmacher SJ, Flisher AJ, Mtshizana YY, Nelson T, McCarthy J, et al. The quality of HIV testing services for adolescents in Cape Town, South Africa: do adolescent-friendly services make a difference? *J Adolesc Health*. 2009;44(2):188–90.
22. Strauss M, Rhodes B, George G. A qualitative analysis of the barriers and facilitators of HIV counselling and testing perceived by adolescents in South Africa. *BMC Health Serv Res*. 2015;15:250.
23. MacPhail CL, Pettifor A, Coates T, Rees H. "You must do the test to know your status": attitudes to HIV voluntary counseling and testing for adolescents among South African youth and parents. *Health Educ Behav*. 2008;35(1):87–104.
24. DiClemente RJ, Crosby RA. Preventing HIV among adolescents in sub-Saharan Africa. *J Adolesc Health*. 2009;44(2):101–2.
25. Tumwebaze H, Tumwesigye E, Baeten JM, Kurth AE, Revall J, Murnane PM, et al. Household-based HIV counseling and testing as a platform for referral to HIV care and medical male circumcision in Uganda: a pilot evaluation. *PLoS One*. 2012;7(12):e51620.
26. Barnabas RV, van Rooyen H, Tumwesigye E, Brantley J, Baeten JM, van Heerden A, et al. Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda. *Lancet HIV*. 2016;3(5):e212–20.
27. Shamu S, Slabbert J, Guloba G, Blom D, Khupakonke S, Masihleho N, et al. Linkage to care of HIV positive clients in a community based HIV counselling and testing programme: a success story of non-governmental organisations in a South African district. *PLoS One*. 2019;14(1):e0210826.
28. Brunie A, Wamala-Mucheri P, Akol A, Mercer S, Chen M. Expanding HIV testing and counselling into communities: feasibility, acceptability, and effects of an integrated family planning/HTC service delivery model by Village Health Teams in Uganda. *Health Policy Plan*. 2016;31(8):1050–7.
29. Medina-Marino A, Bezuidenhout D, Daniels J, Hosek S, Barnabas RV, Atujuna M, et al. The Community PrEP Study: a randomized control trial leveraging community-based platforms to improve access and adherence to pre-exposure prophylaxis to prevent HIV among adolescent girls and young women in South Africa – study protocol. *Trials*. 2021;22:489.
30. South African National Department of Health. South African district level HIV estimates, 2016. Pretoria; 2017.
31. Medina-Marino A, Daniels J, Bezuidenhout D, Peters R, Farirai T, Slabbert J, et al. Outcomes from a multimodal, at-scale community-based HIV counselling and testing programme in twelve high HIV burden districts in South Africa. *J Int AIDS Soc*. 2021;24(3):e25678.
32. South African National Department of Health. HIV Testing Services: Policy 1047. Available from: <https://sahivsoc.org/Files/HTS%20Policy%2028%20July%20final%20copy.pdf>. Accessed: December 15, 2021.

33. Baron D, Ramskin L, Joubert M; Wits Reproductive Health and HIV Institute. Get PrEPared what African women need to know! Johannesburg: Umzi Flims; 2017.
34. Sumartojo E. Structural factors in HIV prevention: concepts, examples, and implications for research. *AIDS*. 2000;14(Suppl 1):S3–10.
35. Rhodes T. The 'risk environment': a framework for understanding and reducing drug-related harm. *Int J Drug Policy*. 2002;13(2):85–94.
36. Gill K, Johnson L, Dietrich J, Myer L, Marcus R, Wallace M, et al. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial. *Lancet Child Adolesc Health*. 2020;4(12):875–83.
37. Digitale JC, Martin JN, Glymour MM. Tutorial on directed acyclic graphs. *J Clin Epidemiol*. 2022;142:264–7.
38. ICAP. Standard operating procedures: pre-exposure prophylaxis (PrEP) screening for substantial risk and eligibility. 2019 [cited 2022 Feb 9]. Available from: https://icap.columbia.edu/wp-content/uploads/SOP_1_PrEP_Screening_for_Substantial_Risk_and_Eligibility_final_3.14.2019.pdf
39. PrEP Watch. Oral PrEP risk assessment tools. [cited 2021 Jul 28]. Available from: <https://www.prepwatch.org/risk-assessment-tools/>
40. Balkus JE, Brown E, Palanee T, Nair G, Gafoor Z, Zhang J, et al. An empiric HIV risk scoring tool to predict HIV-1 acquisition in African women. *J Acquir Immune Defic Syndr*. 2016;72(3):333–43.
41. ICAP. ICAP pre-exposure prophylaxis (PrEP) package. 2019 [cited 2022 Jun 20]. Available from: https://icap.columbia.edu/tools_resources/icap-pre-exposure-prophylaxis-prep-package-2/
42. Balkus JE, Brown ER, Palanee-Phillips T, Matovu Kiweewa F, Mgodini N, Naidoo L, et al. Performance of a validated risk score to predict HIV-1 acquisition among African women participating in a trial of the dapivirine vaginal ring. *J Acquir Immune Defic Syndr*. 2018;77(1):e8–10.
43. Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Gonder V, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. *N Engl J Med*. 2016;375(22):2121–32.
44. Gregson S, Nyamukapa CA, Garnett GP, Mason PR, Zhuwau T, Caraël M, et al. Sexual mixing patterns and sex-differentials in teenage exposure to HIV infection in rural Zimbabwe. *Lancet*. 2002;359(9321):1896–903.
45. Pettifor A, MacPhail C, Rees H, Cohen M. HIV and sexual behavior among young people: the South African paradox. *Sex Transm Dis*. 2008;35(10):843–4.
46. Pettifor AE, Measham DM, Rees HV, Padian NS. Sexual power and HIV risk, South Africa. *Emerg Infect Dis*. 2004;10(11):1996–2004.
47. Mathews C, Guttmacher SJ, Flisher AJ, Mtshizana YY, Nelson T, McCarthy J, et al. The quality of HIV testing services for adolescents in Cape Town, South Africa: do adolescent-friendly services make a difference? *J Adolesc Health*. 2009;44(2):188–90.
48. Strauss M, Rhodes B, George G. A qualitative analysis of the barriers and facilitators of HIV counselling and testing perceived by adolescents in South Africa. *BMC Health Serv Res*. 2015;15:250.
49. DiClemente RJ, Crosby RA. Preventing HIV among adolescents in sub-Saharan Africa. *J Adolesc Health*. 2009;44(2):101–2.
50. MacPhail CL, Pettifor A, Coates T, Rees H. "You must do the test to know your status": attitudes to HIV voluntary counselling and testing for adolescents among South African youth and parents. *Health Educ Behav*. 2008;35(1):87–104. Epub 2006 Jul 26.
51. Hagey JM, Akama E, Ayieko J, Bukusi EA, Cohen CR, Patel RC. Barriers and facilitators adolescent females living with HIV face in accessing contraceptive services: a qualitative assessment of providers' perceptions in western Kenya. *J Int AIDS Soc*. 2015;18(1):20123.
52. McLaren ZM, Ardington C, Leibbrandt M. Distance decay and persistent health care disparities in South Africa. *BMC Health Serv Res*. 2014;14(1):541.
53. Kiapi-iwa L, Hart GJ. The sexual and reproductive health of young people in Adjumani district, Uganda: qualitative study of the role of formal, informal and traditional health providers. *AIDS Care*. 2004;16(3):339–47.
54. Mudzingwa EK, de Vos L, Atujuna M, Fynn L, Mugore M, Hosek S, et al. Factors influencing adolescent girls and young women's uptake of community-based PrEP services following home-based HIV testing in Eastern Cape, South Africa: a qualitative study. *AIDS Behav*. 2022 Jun 2. <https://doi.org/10.1007/s10461-022-03702-9>. Epub ahead of print.
55. Quaife M, Terris-Prestholt F, Eakle R, Cabrera Escobar MA, Kilbourne-Brook M, Mvundura M, et al. The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa. *J Int AIDS Soc*. 2018;21(3):e25064.
56. Schneider H, Hlophe H, van Rensburg D. Community health workers and the response to HIV/AIDS in South Africa: tensions and prospects. *Health Policy Plan*. 2008;23(3):179–87.
57. Mudimu E, Sardinia J, Momin S, Medina-Marino A, Bezuidenhout C, Bekker L, et al. Incremental costs of integrated PrEP provision and effective use counselling in community-based platforms for adolescent girls and young women in South Africa: an observational study. *J Int AIDS Soc*. 2022;25(2):e25875.
58. Koss CA, Charlebois ED, Ayieko J, Kwarisiima D, Kabami J, Balzer LB, et al. Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study. *Lancet HIV*. 2020;7(4):e249–61.
59. Kamis KF, Marx GE, Scott KA, Gardner EM, Wendel KA, Scott ML, et al. Same-day HIV pre-exposure prophylaxis (PrEP) initiation during drop-in sexually transmitted diseases clinic appointments is a highly acceptable, feasible, and safe model that engages individuals at risk for HIV into PrEP care. *Open Forum Infect Dis*. 2019;6(7):ofz310.
60. Khosropour CM, Backus KV, Means AR, Beauchamps L, Johnson K, Golden MR, et al. A pharmacist-led, same-day, HIV pre-exposure prophylaxis initiation program to increase PrEP uptake and decrease time to PrEP initiation. *AIDS Patient Care STDs*. 2020;34(1):1–6.
61. Rowan SE, Patel RR, Schneider JA, Smith DK. Same-day prescribing of daily oral pre-exposure prophylaxis for HIV prevention. *Lancet HIV*. 2021;8(2):e114–20.
62. Koss CA, Ayieko J, Mwangwa F, Owaraganise A, Kwarisiima D, Balzer LB, et al. Early adopters of human immunodeficiency virus preexposure prophylaxis in a population-based combination prevention study in rural Kenya and Uganda. *Clin Infect Dis*. 2018;67(12):1853–60.
63. Bekker LG, Brown B, Joseph-Davey D, Gill K, Moorhouse M, Delany-Moretlwe S, et al. Southern African guidelines on the safe, easy and effective use of pre-exposure prophylaxis: 2020. *South Afr J HIV Med*. 2020;21(1):1152.
64. Delany-Moretlwe S, Mgodini N, Bekker LG, Baeten J, Pathak S, Donnell D, et al. High curable STI prevalence and incidence among young African women initiating PrEP in HPTN 082. *Sex Transm Infect*. 2019;95(Suppl 1):A60–1.
65. Stewart J, Omollo V, Odoyo J, Kidoguchi L, Morton J, Johnson R, et al. High prevalence and incidence of bacterial STIs in young women at high risk of HIV prior to PrEP scale-up in Kenya. *Sex Transm Infect*. 2019;95(Suppl 1):A202.
66. White RG, Moodley P, McGrath N, Hosegood V, Zaba B, Herbst K, et al. Low effectiveness of syndromic treatment services for curable sexually transmitted infections in rural South Africa. *Sex Transm Infect*. 2008;84(7):528–34.
67. Stewart J, Bukusi E, Sesay FA, Oware K, Donnell D, Soge OO, et al. Doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections among Kenyan women using HIV pre-exposure prophylaxis: study protocol for an open-label randomized trial. *Trials*. 2022;23(1):495.
68. World Health Organization. Listings of WHO's response to COVID-19. 2020 [cited 2022 Jan 5]. Available from: <https://www.who.int/news/item/29-06-2020-covidtimeline>
69. National Institute for Communicable Diseases. First case of COVID-19 Coronavirus reported in South Africa. South Africa: National Institute for Communicable Diseases; 2020.
70. South African National Department of Health. COVID-19 South African Online Resources & News Portal. [cited 2022 Jan 5]. Available from: <https://sacoronavirus.co.za/information-about-the-virus-2/>
71. Davey DLJ, Bekker LG, Mashele N, Gorbach P, Coates TJ, Myer L. PrEP retention and prescriptions for pregnant women during COVID-19 lockdown in South Africa. *Lancet HIV*. 2020;7(11):e735.
72. Pampati S, Emrick K, Siegler AJ, Jones J. Changes in sexual behavior, PrEP adherence, and access to sexual health services because of the COVID-19 pandemic among a cohort of PrEP-using MSM in the South. *J Acquir Immune Defic Syndr*. 2021;87(1):639–43.
73. Dorward J, Khubone T, Gate K, Ngobese H, Sookrajah Y, Mkhize S, et al. The impact of the COVID-19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis. *Lancet HIV*. 2021;8(3):e158–65.
74. Wilkinson L, Grimsrud A. The time is now: expedited HIV differentiated service delivery during the COVID-19 pandemic. *J Int AIDS Soc*. 2020;23(5):e25503.
75. Barnabas RV, Szpiro AA, van Rooyen H, Asiimwe S, Pillay D, Ware NC, et al. Community-based antiretroviral therapy versus standard clinic-based services for HIV in South Africa and Uganda (DO ART): a randomised trial. *Lancet Glob Health*. 2020;8(10):e1305–15.
76. Vrazo AC, Golin R, Fernando NB, Killam WP, Sharifi S, Phelps BR, et al. Adapting HIV services for pregnant and breastfeeding women, infants, children, adolescents and families in resource-constrained settings during the COVID-19 pandemic. *J Int AIDS Soc*. 2020;23(9):e25622.
77. World Health Organization, United Nations Children's Fund (UNICEF). Community-based health care, including outreach and campaigns, in the context of the COVID-19 pandemic. 2020 [cited 2022 Feb 9]. Available from: <https://www.unicef.org/media/68811/file/Guidance-Community-based-Health-Care.pdf>

78. Mash RJ, Schouw D, Daviaud E, Besada D, Roman D. Evaluating the implementation of home delivery of medication by community health workers during the COVID-19 pandemic in Cape Town, South Africa: a convergent mixed methods study. *BMC Health Serv Res.* 2022;22(1):98.

SUPPORTING INFORMATION

Additional information may be found under the Supporting Information tab for this article:

Table S1: Enrolment Scripts.

Table S2: Socio-demographic and behavioural factors associated with presentation for PrEP services among AGYW receiving home-based HTS.

Table S3: Application of risk assessment tools to the community PrEP study participants.

Table S4: Implementation indicators.